Portola Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Portola Pharmaceuticals's estimated annual revenue is currently $24M per year.
- Portola Pharmaceuticals received $345.0M in venture funding in September 2017.
- Portola Pharmaceuticals's estimated revenue per employee is $363,636
- Portola Pharmaceuticals's total funding is $1.3B.
Employee Data
- Portola Pharmaceuticals has 66 Employees.
- Portola Pharmaceuticals grew their employee count by -4% last year.
Portola Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Portola Pharmaceuticals?
We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.3B
Total Funding
66
Number of Employees
$24M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Portola Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Scientist I | Reveal Email/Phone |
Portola Pharmaceuticals News
Aldeyra Therapeutics, Allergan, OHR Pharmaceutical, Portola Pharmaceuticals, Sylentis, Bausch + Lomb. This comprehensive Allergic Conjunctivitis Treatments...
Array BioPharma Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Bristol-Myers Squibb ... Takeda Pharmaceutical Company Ltd, and Theravance Biopharma Inc.
Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc | Medgadget...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.3M | 66 | -3% | $80.9M |
#2 | $5.1M | 66 | 10% | $148.6M |
#3 | $9.3M | 69 | 3% | N/A |
#4 | $17.6M | 70 | 6% | N/A |
#5 | $15M | 72 | 0% | N/A |
Portola Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-12-09 | $21.0M | A | Multiple | Article |
| 2005-01-19 | $21.0M | A | Sutter Hill Ventures, Prospect Ventures | Article |
| 2005-11-09 | $46.0M | B | Advanced Technology Ventures | Article |
| 2006-10-18 | $20.0M | Undisclosed | Hercules Technology Growth Cap | Article |
| 2007-05-08 | $70.0M | C | Multiple | Article |
| 2008-07-10 | $60.0M | Undisclosed | Multiple | Article |
| 2011-11-22 | $89.0M | Undsiclosed | Temasek | Article |
| 2014-10-06 | $185.4M | Undisclosed | Morgan Stanley | Article |
| 2015-03-11 | $100.0M | Undisclosed | Morgan Stanley | Article |
| 2017-09-13 | $345.0M | Undisclosed | Morgan Stanley | Article |